6078.HK
Hygeia Healthcare Holdings Co., Limited [6078.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
6078.HK Stock Summary
Top 10 Correlated Stocks
6078.HK
In the News
6078.HK Financial details
Company Rating
Buy
Market Cap
19.26B
Income
1.05B
Revenue
6.34B
Book val./share
9.31
Cash/share
2.38
Dividend
0.16
Dividend %
0.58%
Employees
8.24K
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
36.52
Forward P/E
-
PEG
2.65
P/S
5.58
P/B
3.53
P/C
12.08
P/FCF
227.14
Quick Ratio
0.86
Current Ratio
1.71
Debt / Equity
0.3
LT Debt / Equity
0.24
-
-
EPS (TTM)
1.69
EPS next Y
-
EPS next Q
-
EPS this Y
8.45%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
182.23%
Revenue last 5Y
33.06%
Revenue Q/Q
5.4%
EPS Q/Q
29.27%
-
-
-
-
SMA20
3.45%
SMA50
11.11%
SMA100
-37.5%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
10%
ROC
0.11%
Gross Margin
32%
Oper. Margin
21%
Profit Margin
15%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
23.55-62.75
52W High
-53.63%
52W Low
+25%
RSI
49
Rel Volume
0.78
Avg Volume
2.9M
Volume
2.27M
Perf Week
-6.96%
Perf Month
-3.04%
Perf Quarter
-33.29%
Perf Half Y
-34.73%
-
-
-
-
Beta
0.28
-
-
Volatility
0.9%, 1.45%
Prev Close
-0.86%
Price
28.75
Change
-1.88%
6078.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.28 | 1.81 | 3.14 | 3.75 | 5.18 | |
| Net income per share | 0 | 0.07 | 0.38 | 0.71 | 0.77 | |
| Operating cash flow per share | 0.27 | 0.38 | 0.66 | 0.69 | 1.11 | |
| Free cash flow per share | -0.22 | 0.11 | -0.06 | -0.38 | 0.15 | |
| Cash per share | 0.32 | 0.66 | 5.78 | 1.79 | 1.43 | |
| Book value per share | -0.32 | -0.34 | 9.56 | 7.21 | 8 | |
| Tangible book value per share | -0.95 | -0.98 | 8.86 | 3.39 | 4.14 | |
| Share holders equity per share | -0.32 | -0.34 | 9.56 | 7.21 | 8 | |
| Interest debt per share | 0.22 | 0.16 | 0.11 | 2.03 | 2.15 | |
| Market cap | 13.69B | 13.93B | 18.45B | 24.61B | 30.5B | |
| Enterprise value | 13.55B | 13.54B | 18.07B | 25.14B | 30.94B | |
| P/E ratio | 5.29K | 350.27 | 108.49 | 55.76 | 63.98 | |
| Price to sales ratio | 17.87 | 12.83 | 13.16 | 10.63 | 9.55 | |
| POCF ratio | 85.59 | 60.93 | 62.32 | 57.74 | 44.51 | |
| PFCF ratio | -104.76 | 201.99 | -716.13 | -103.93 | 330.64 | |
| P/B Ratio | -71.35 | -68.75 | 4.32 | 5.52 | 6.18 | |
| PTB ratio | -71.35 | -68.75 | 4.32 | 5.52 | 6.18 | |
| EV to sales | 17.69 | 12.47 | 12.89 | 10.86 | 9.68 | |
| Enterprise value over EBITDA | 88.3 | 53.05 | 46.89 | 40.31 | 35.63 | |
| EV to operating cash flow | 84.75 | 59.22 | 61.02 | 58.98 | 45.14 | |
| EV to free cash flow | -103.73 | 196.33 | -701.28 | -106.14 | 335.36 | |
| Earnings yield | 0 | 0 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | -0.01 | 0 | 0 | -0.01 | 0 | |
| Debt to equity | -0.29 | -0.01 | 0 | 0.28 | 0.26 | |
| Debt to assets | 0.03 | 0 | 0 | 0.18 | 0.18 | |
| Net debt to EBITDA | -0.88 | -1.53 | -0.99 | 0.84 | 0.5 | |
| Current ratio | 1.24 | 0.39 | 10.4 | 2.01 | 1.71 | |
| Interest coverage | 1.35 | 1.82 | 6.6 | 22.77 | 18.02 | |
| Income quality | 5.87 | 2.88 | 1.74 | 0.97 | 1.44 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 6.65 | 0 | 0.41 | 0.17 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.05 | 0.1 | 0.09 | 0.08 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.19 | 0.17 | 0.08 | 0.36 | 0.33 | |
| Capex to operating cash flow | -1.82 | -0.7 | -1.09 | -1.56 | -0.87 | |
| Capex to revenue | -0.38 | -0.15 | -0.23 | -0.29 | -0.19 | |
| Capex to depreciation | -5.94 | -2.24 | -4.31 | -6.02 | -4.03 | |
| Stock based compensation to revenue | 0.02 | 0.01 | 0 | 0 | 0.01 | |
| Graham number | 0.18 | 0.71 | 9.05 | 10.77 | 11.79 | |
| ROIC | -0.07 | -0.44 | 0.05 | 0.07 | 0.09 | |
| Return on tangible assets | 0 | 0.02 | 0.04 | 0.1 | 0.1 | |
| Graham Net | -3.07 | -3.08 | 5.49 | -1.13 | -1.39 | |
| Working capital | 97.66M | -1.05B | 2.64B | 866.17M | 723.44M | |
| Tangible asset value | -571.65M | -588.31M | 3.96B | 2.1B | 2.56B | |
| Net current asset value | -1.66B | -1.75B | 2.56B | -488.45M | -552.41M | |
| Invested capital | -0.29 | -0.01 | 0 | 0.28 | 0.26 | |
| Average receivables | 138.03M | 180.64M | 236.52M | 361.76M | 532.95M | |
| Average payables | 93.96M | 110.68M | 118.62M | 213.4M | 352.28M | |
| Average inventory | 38.17M | 44.02M | 53.41M | 98.07M | 170.26M | |
| Days sales outstanding | 74.83 | 68.65 | 70 | 71.68 | 69.81 | |
| Days payables outstanding | 70.99 | 57.37 | 46.5 | 71.65 | 66.38 | |
| Days of inventory on hand | 28.39 | 22.71 | 23.47 | 31.68 | 34.21 | |
| Receivables turnover | 4.88 | 5.32 | 5.21 | 5.09 | 5.23 | |
| Payables turnover | 5.14 | 6.36 | 7.85 | 5.09 | 5.5 | |
| Inventory turnover | 12.86 | 16.07 | 15.55 | 11.52 | 10.67 | |
| ROE | -0.01 | -0.2 | 0.04 | 0.1 | 0.1 | |
| Capex per share | -0.48 | -0.27 | -0.72 | -1.07 | -0.96 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.51 | 2.24 | 2.45 | 2.71 | 2.79 | |
| Net income per share | 0.32 | 0.39 | 0.36 | 0.41 | 0.53 | |
| Operating cash flow per share | 0.26 | 0.43 | 0.47 | 0.64 | 0.56 | |
| Free cash flow per share | -0.14 | -0.24 | 0.05 | 0.1 | -0.31 | |
| Cash per share | 2.78 | 1.79 | 1.61 | 1.43 | 2.38 | |
| Book value per share | 7.11 | 7.21 | 7.49 | 8 | 9.31 | |
| Tangible book value per share | 4.21 | 3.39 | 3.71 | 4.14 | 5.27 | |
| Share holders equity per share | 7.11 | 7.21 | 7.49 | 8 | 9.31 | |
| Interest debt per share | 1.61 | 1.99 | 2.07 | 2.09 | 2.82 | |
| Market cap | 52.48B | 24.61B | 27.72B | 30.5B | 24.71B | |
| Enterprise value | 52.78B | 25.14B | 28.12B | 30.93B | 25.12B | |
| P/E ratio | 66.4 | 25.23 | 30.91 | 30.19 | 18.49 | |
| Price to sales ratio | 56.33 | 17.79 | 18.16 | 18.27 | 14.05 | |
| POCF ratio | 321.98 | 93.5 | 95.19 | 77.38 | 70.58 | |
| PFCF ratio | -599.88 | -164.81 | 862.03 | 507.48 | -126.2 | |
| P/B Ratio | 11.95 | 5.52 | 5.94 | 6.18 | 4.21 | |
| PTB ratio | 11.95 | 5.52 | 5.94 | 6.18 | 4.21 | |
| EV to sales | 56.65 | 18.17 | 18.43 | 18.53 | 14.28 | |
| Enterprise value over EBITDA | 189.93 | 72.71 | 66.4 | 69.53 | 52.48 | |
| EV to operating cash flow | 323.82 | 95.49 | 96.58 | 78.48 | 71.74 | |
| EV to free cash flow | -603.3 | -168.32 | 874.57 | 514.73 | -128.27 | |
| Earnings yield | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | -0.01 | 0 | 0 | -0.01 | |
| Debt to equity | 0.23 | 0.28 | 0.28 | 0.26 | 0.3 | |
| Debt to assets | 0.16 | 0.18 | 0.19 | 0.18 | 0.2 | |
| Net debt to EBITDA | 1.08 | 1.52 | 0.95 | 0.98 | 0.85 | |
| Current ratio | 3.48 | 2.01 | 1.96 | 1.71 | 1.66 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.82 | 1.08 | 1.3 | 1.56 | 1.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.3 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.08 | 0.1 | 0.09 | 0.08 | 0.1 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.3 | 0.36 | 0.34 | 0.33 | 0.29 | |
| Capex to operating cash flow | -1.54 | -1.57 | -0.89 | -0.85 | -1.56 | |
| Capex to revenue | -0.27 | -0.3 | -0.17 | -0.2 | -0.31 | |
| Capex to depreciation | -5.53 | -6.37 | -3.68 | -4.35 | -6.42 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Graham number | 7.15 | 8 | 7.79 | 8.59 | 10.54 | |
| ROIC | 0.04 | 0.04 | 0.04 | 0.05 | 0.04 | |
| Return on tangible assets | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | |
| Graham Net | 0.51 | -1.13 | -1.13 | -1.39 | -1.53 | |
| Working capital | 1.58B | 866.17M | 861.78M | 723.44M | 964.48M | |
| Tangible asset value | 2.6B | 2.1B | 2.31B | 2.56B | 3.33B | |
| Net current asset value | 473.58M | -488.45M | -460.57M | -552.41M | -647.44M | |
| Invested capital | 0.23 | 0.28 | 0.28 | 0.26 | 0.3 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 37.02 | 29.57 | 34.34 | 32.95 | 33.62 | |
| Days payables outstanding | 28.89 | 29.23 | 28.82 | 31.13 | 30.29 | |
| Days of inventory on hand | 13.2 | 12.93 | 12.91 | 16.04 | 15.85 | |
| Receivables turnover | 2.43 | 3.04 | 2.62 | 2.73 | 2.68 | |
| Payables turnover | 3.12 | 3.08 | 3.12 | 2.89 | 2.97 | |
| Inventory turnover | 6.82 | 6.96 | 6.97 | 5.61 | 5.68 | |
| ROE | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | |
| Capex per share | -0.41 | -0.67 | -0.42 | -0.54 | -0.87 |
6078.HK Frequently Asked Questions
What is Hygeia Healthcare Holdings Co., Limited stock symbol ?
Hygeia Healthcare Holdings Co., Limited is a CN stock and trading under the symbol 6078.HK
What is Hygeia Healthcare Holdings Co., Limited stock quote today ?
Hygeia Healthcare Holdings Co., Limited stock price is $28.75 today.
Is Hygeia Healthcare Holdings Co., Limited stock public?
Yes, Hygeia Healthcare Holdings Co., Limited is a publicly traded company.
Company Profile
- Volume Average 2.9M
- Market Capitalization 19.26B
- Employee 8.24K
- CEO Mr. Yiwen Zhu
- Headquarters Shanghai,CN
- IPO Date 2020-06-29
-
Website
https://www.hygeia-group.com.cn 
Hygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
